Why the study?
Does sunitinib improve tumor response in a patient with refractory retroperitoneal angiosarcoma?
Does sunitinib improve tumor response in a patient with refractory retroperitoneal angiosarcoma?
Sunitinib may be an effective salvage therapy for angiosarcoma, though severe hematologic toxicity requires close monitoring.
No takes yet. Share an insight, caveat, or question.
May support sunitinib salvage consideration in refractory angiosarcoma with toxicity monitoring; leaves open confirmation in prospective trials.
Yoo et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: